


PathVysion (CE) for Breast and Gastric Cancer

PathVysion for greater confidence in treatment decisions

Molecular science for proven accurate results


The PathVysion HER-2 DNA Probe Kit utilizes proprietary FISH technology to deliver **precision, accuracy, reproducibility,** and **objectivity** with:

- Probes that detect stable DNA targets
- Control probe (centromere) to determine gene-to-chromosome ratio
- Proprietary direct fluorescence labeling technique
- Objective measure of HER-2/neu gene amplification





Probe Description (This set is premixed in Hybridization Buffer)				
Probe Name	Probe Location	Fluorophore		
Vysis LSI HER-2/neu	17q11.2-q12	SpectrumOrange		
Vysis CEP 17	17p11.1-q11.1 Alpha Satellite DNA	SpectrumGreen		



PathVysion HER-2 DNA Probe Kit II

The PathVysion HER-2 DNA Probe Kit II (PathVysion Kit II) is designed to detect amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded human breast and gastric cancer tissue specimens.

The PathVysion Kit II is indicated as an aid in the assessment of breast cancer patients for whom HERCEPTIN® (trastuzumab) treatment is being considered (see HERCEPTIN package insert).



Ordering Information

PathVysion HER-2 DNA Probe Kit II contains:

- LSI HER-2/neu SpectrumOrange/CEP 17 SpectrumGreen DNA Probe
- DAPI Counterstain
- 20X SSC
- NP-40

Probe Kit Storage: -20°C, protected from light

Order No.	Kit Name	Breast Cancer	Gastric Cancer	
LN 06N46-030	PathVysion HER-2 DNA Probe Kit II (20 assays)	Yes	Yes	
LN 06N46-035	PathVysion HER-2 DNA Probe Kit II (50 assays)	Yes	Yes	
LN 06N46-036	PathVysion HER-2 DNA Probe Kit II (100 assays)	Yes	Yes	
LN 02J02-032	Vysis Paraffin Pretreatment Reagent Kit	Yes	_	
LN 02J04-030	ProbeChek HER-2/neu Cutoff Control Slides	Yes	_	
LN 02J05-030	ProbeChek HER-2/neu Normal Control Slides	Yes	_	
The new kit contains specific protocols for Gastric Cancer, including a manual protocol and also a semiautomated protocol using the VP2000 instrument. The following reagents are available for the Gastric Cancer protocols.				
LN 06N46-001	Protease IV (5 x 75 mg) (General-Purpose Reagent for Pretreatment), manual protocol	_	Yes	
LN 06N46-002	Protease IV (5 x 750 mg) (General-Purpose Reagent for Pretreatment), VP2000 protocol	_	Yes	

Innovative science from Abbott Molecular: Moving molecular diagnostics forward

For more information, visit www.abbottmolecular.com.

